e-Article
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Document Type
Article
Author
Janjigian, Yelena Y ; Maron, Steven B; Chatila, Walid K; Millang, Brittanie; Chavan, Shweta S; Alterman, Carly; Chou, Joanne F; Segal, Michal F; Simmons, Marc Z; Momtaz, Parisa; Shcherba, Marina; Ku, Geoffrey Y; Zervoudakis, Alice; Won, Elizabeth S; Kelsen, David P; Ilson, David H; Nagy, Rebecca J; Lanman, Richard B; Ptashkin, Ryan N; Donoghue, Mark T A; Capanu, Marinela; Taylor, Barry S; Solit, David B; Schultz, Nikolaus; Hechtman, Jaclyn F
Source
In The Lancet Oncology June 2020 21(6):821-831
Subject
Language
ISSN
1470-2045